# FDA Grants Accelerated Approval to Vera Therapeutics' Trutakna for IgA Nephropathy

> fda · REPORTED · 2026-07-07

The FDA granted accelerated approval to atacicept-vymj (Trutakna) on July 7, 2026, making it the first dual BAFF and APRIL inhibitor cleared for adults with primary IgA nephropathy at risk of disease progression. The self-administered weekly autoinjector was backed by Phase 3 ORIGIN 3 trial data showing a 46% reduction in proteinuria versus placebo.

About Vera Therapeutics: Vera Therapeutics is a clinical-stage biotech focused on autoimmune kidney diseases, developing atacicept, a fusion protein that blocks two key cytokines driving IgA nephropathy progression.

- Company: Vera Therapeutics
- Sector: biotech
- Primary source: https://www.ajmc.com/view/fda-approves-atacicept-for-iga-nephropathy

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.